Abstract
Albumin has been used as a popular material for carrying imaging probes and/or drugs to provide efficient biomedical imaging and therapy. It is considered as an ideal material for in vivo applications, because albumin is naturally abundant in serum to show non-toxicity and non-immunogenicity. In addition, based on the convenience of chemical modifications, it is widely used for the delivery of diverse molecules including chemicals, proteins/peptides, and oligonucleotides. Albumin nanoparticles carrying these molecules have shown improved pharmacokinetic properties by providing longer circulation time and more disease-specific accumulation, and they are emerging as a promising carrier system for in vivo imaging and therapy. Constant efforts to improve the properties of albumin nanoparticles have led to a great progress in medical application, and recent examples of market approval and success are brightening the prospect of albumin-based nanocarrier formulations in the future. This article will summarize the developments in albumin nanocarriers for biomedical imaging and targeted drug delivery. This review will give an account of the different applications of albumin carriers with examples of some recent innovative works.
Keywords: Albumin, biomedical imaging, nanoparticle, targeted drug delivery.
Current Pharmaceutical Design
Title:Molecular Imaging and Targeted Drug Delivery Using Albumin-Based Nanoparticles
Volume: 21 Issue: 14
Author(s): Ji Young Yhee, Jangwook Lee, Hyeyoun Chang, Jeewon Lee, Ick Chan Kwon and Kwangmeyung Kim
Affiliation:
Keywords: Albumin, biomedical imaging, nanoparticle, targeted drug delivery.
Abstract: Albumin has been used as a popular material for carrying imaging probes and/or drugs to provide efficient biomedical imaging and therapy. It is considered as an ideal material for in vivo applications, because albumin is naturally abundant in serum to show non-toxicity and non-immunogenicity. In addition, based on the convenience of chemical modifications, it is widely used for the delivery of diverse molecules including chemicals, proteins/peptides, and oligonucleotides. Albumin nanoparticles carrying these molecules have shown improved pharmacokinetic properties by providing longer circulation time and more disease-specific accumulation, and they are emerging as a promising carrier system for in vivo imaging and therapy. Constant efforts to improve the properties of albumin nanoparticles have led to a great progress in medical application, and recent examples of market approval and success are brightening the prospect of albumin-based nanocarrier formulations in the future. This article will summarize the developments in albumin nanocarriers for biomedical imaging and targeted drug delivery. This review will give an account of the different applications of albumin carriers with examples of some recent innovative works.
Export Options
About this article
Cite this article as:
Yhee Young Ji, Lee Jangwook, Chang Hyeyoun, Lee Jeewon, Kwon Chan Ick and Kim Kwangmeyung, Molecular Imaging and Targeted Drug Delivery Using Albumin-Based Nanoparticles, Current Pharmaceutical Design 2015; 21 (14) . https://dx.doi.org/10.2174/1381612821666150302115809
DOI https://dx.doi.org/10.2174/1381612821666150302115809 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MicroRNAs in Glioblastoma: Role in Pathogenesis and Opportunities for Targeted Therapies
CNS & Neurological Disorders - Drug Targets Natural Sourced Inhibitors of EGFR, PDGFR, FGFR and VEGFRMediated Signaling Pathways as Potential Anticancer Agents
Current Medicinal Chemistry Design of Combretastatin A-4 Analogs as Tubulin Targeted Vascular Disrupting Agent with Special Emphasis on Their Cis-Restricted Isomers
Current Pharmaceutical Design Blockade of Insulin-Like Growth Factor Type-1 Receptor with Cixutumumab (IMC-A12): A Novel Approach to Treatment for Multiple Cancers
Current Drug Targets Recent Developments in the Third Generation Inhibitors of Bcr-Abl for Overriding T315I Mutation
Current Medicinal Chemistry Urinary Tract Tumors, Biology and Risk for Artificial Sweeteners Use with Particular Emphasis on some South American Countries
Current Nutrition & Food Science Therapeutic Transfer of DNA Encoding Adenoviral E1A
Recent Patents on Anti-Cancer Drug Discovery Adverse Drug Reactions in the Oral Cavity
Current Pharmaceutical Design Ceramidases in Hematological Malignancies: Senseless or Neglected Target?
Anti-Cancer Agents in Medicinal Chemistry Nanoparticles in Melanoma
Current Medicinal Chemistry Role of Vitamin D in Vascular Complications and Vascular Access Outcome in Patients with Chronic Kidney Disease
Current Medicinal Chemistry Ribonucleotide Reductase: A Critical Enzyme for Cancer Chemotherapy and Antiviral Agents
Recent Patents on Anti-Cancer Drug Discovery Pharmacologic Ovarian Preservation in Young Women Undergoing Chemotherapy
Current Medicinal Chemistry Supercritical Fluid Particle Design of DPI Formulations (Review)
Current Pharmaceutical Design Progress Toward Vector Design for Hematopoietic Stem Cell Gene Therapy
Current Gene Therapy Metallothioneins and Cancer
Current Protein & Peptide Science Genistein Potentiates the Anti-cancer Effects of Gemcitabine in Human Osteosarcoma via the Downregulation of Akt and Nuclear Factor-κB Pathway
Anti-Cancer Agents in Medicinal Chemistry Delivery of Intracellular-Acting Biologics in Pro-Apoptotic Therapies
Current Pharmaceutical Design Pyruvate Kinase M2: Regulatory Circuits and Potential for Therapeutic Intervention
Current Pharmaceutical Design Editorial [Hot Topic: Molecular Targeted Therapy of Gastrointestinal Cancer (Guest Editor: Marcus W. Wiedmann)]
Current Cancer Drug Targets